Jessie Au, Pharm.D., Ph.D., Chief Scientific Officer and CEO
Dr. Au received her Pharm.D. and Ph.D. degrees from University of California San Francisco and postdoctoral training at Roswell Park Cancer Institute. Dr. Au is recognized for her accomplishments in pharmaceutical and cancer research. Her breadth of interests and training in both clinical and basic sciences have allowed her to excel in translating her laboratory discoveries in cellular and molecular pharmacology of anticancer drugs into clinical applications. Dr. Au is among the top 5% recipients of NIH funding over 25 years.
Ze Lu, Ph.D., Senior Research Scientist
Dr. Lu has been with Optimum since its inception and acts as Principal Investigator on the tumor-penetrating microparticles (TPM) and paclitaxel nanoparticles (PNP) projects.
